ClinicalTrials.gg
RecruitingNCT05959694Updated Oct 23, 2023

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

A Phase 1/2 interventional study of TQB3909 tablet in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 25 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China — 39 open to participants now, 60 under way, 19 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · China.

Planned enrollment
40th of 105
107 · median 89
Started
2023
with 8 others
Phase 1/2
27 of 108
10 open now
Primary completion
2025-12
later than 17 of 59 live
Registered
81st of 108
by date

Among the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, this one is the 40th largest by planned enrollment of the 105 interventional ones that give a count, is one of 9 that started in 2023, is one of 27 in phase 1/2, reaches primary completion later than 17 of the 59 other live ones, and was the 81st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

39 of the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, or all of them as a file.
02

Study summary

This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects volunteered to join the study and signed form (ICF) with good compliance;
  • Age: ≥ 18 years old, ≤75 years old (when signing ICF); Performance Status (ECOG PS) score: 0-1; The expected survival period is more than 3 months;
  • Subjects: patients diagnosed as CLL/SLL according to the revised diagnostic criteria of 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines;
  • Computed Tomography / Magnetic Resonance Imaging (CT/MRI) of patients with SLL showed ;
  • Female subjects of childbearing age should agree to use measures (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; serum pregnancy/urine pregnancy test within 7 days before study enrollment;

Exclusion criteria

Exclusion Criteria:

  • Complicated diseases and medical history:

    1. It has appeared or is currently suffering from other malignant tumors within 3 years before the first medication. The following two situations can be included in the group: other malignant tumors treated by single surgery have achieved disease-free survival (DFS) for five consecutive years; Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
    2. Lymphoma/leukemia is known to involve the central nervous system (CNS);
    3. Previously received hematopoietic stem cell transplantation;
    4. Received autologous hematopoietic stem cell transplantation within 3 months before the first medication;
    5. Unresolved toxic reaction ≥ grade 1 caused by any previous treatment;
    6. Arterial/venous thrombotic events occurred within 6 months before the first medication, such as cerebrovascular accidents (including , cerebral hemorrhage and cerebral infarction), deep venous thrombosis and pulmonary embolism;
    7. Subjects with any serious and/or uncontrollable diseases;
  • Tumor-related symptoms and treatment:

    1. He has received chemotherapy and radiotherapy within 4 weeks before the first medication, and Chimeric Antigen Receptor T (CAR-T)-Cell Immunotherapy within 12 weeks before the first medication, and other small molecule anti-tumor treatments (the elution period is calculated from the end of the last treatment) before the first medication are within 5 half-lives;
    2. previously received BCL-2 inhibitors;
  • Research-related treatment: received the vaccine within 4 weeks before the first medication, or planned to be vaccinated during the study;
  • Participated in clinical trials of other antineoplastic drugs within 4 weeks before the first medication;
  • According to the investigators' judgment, there are patients with accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who think that there are other reasons that are not suitable for inclusion.
  • Allergic to allopurinol and benzbromarone.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (estimated)

Study arms

  • Experimental
    TQB3909 tablets

    Oral administration, 400mg or 600 mg, once a day, and 28 days is a treatment cycle. Continue medication until the disease progresses or intolerant toxicity appears.

    Drug: TQB3909 tablet

Interventions

  • TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AE)

    Incidence of AE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).

    Time frame: Up to 34 months.

  2. Severity of adverse events (AE)

    Severity of AE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).

    Time frame: Up to 34 months.

  3. Incidence of serious adverse events (SAE)

    Incidence of SAE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).

    Time frame: Up to 34 months.

  4. Severity of serious adverse events (SAE)

    Severity of SAE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).

    Time frame: Up to 34 months.

  5. Incidence of abnormal laboratory examination indexes.

    Incidence of abnormal laboratory examination indexes evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).

    Time frame: Up to 34 months.

  6. Severity of abnormal laboratory examination indexes.

    Severity of abnormal laboratory examination indexes evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).

    Time frame: Up to 34 months.

  7. Recommended phase II dose (RP2D)

    To determine the recommended phase II dose of TQB3909 tablets in the treatment of recurrent or refractory CLL/SLL.

    Time frame: Up to 18 months

  8. Objective remission rate (ORR) determined by Independent Review Committee (IRC)

    Determine the objective remission rate (ORR) based on the evaluation results of the Independent Review Committee (IRC), defined as the proportion of subjects whose best remission is complete remission (CR) and partial remission (PR).

    Time frame: Up to 34 months

Secondary outcomes

  1. Objective remission rate (ORR) determined by the investigators' evaluation.

    The objective remission rate (ORR) was determined by the results of the investigator s' evaluation, defined as the proportion of subjects whose best remission is complete remission (CR) and partial remission (PR).

    Time frame: Up to 34 months

  2. Duration of remission (DOR)

    For all subjects whose best response was PR, CR,, the time from the date of first achieving PR, CR to the date of first definite disease progression or death from any cause (whichever occurs first).

    Time frame: Up to 34 months

  3. Time to disease progression (TTP)

    Refers to the time from the first medication to the objective progress of the disease.

    Time frame: Up to 34 months

  4. Time to remission (TTR)

    Time from the beginning of treatment to the first recording of remission (PR or better remission), only the remission population was analyzed.

    Time frame: Up to 34 months

  5. Progression-free survival (PFS)

    The time from the first medication to the objective progression of the disease or death caused from any cause (whichever comes first).

    Time frame: Up to 34 months

  6. Overall survival (OS)

    Time from first dose of study drug to date of death from any cause.

    Time frame: Up to 34 months

  7. Time to reach maximum concentration (Tmax)

    Time to reach maximum plasma concentration after single and multiple dosing of TQB3909 tablets.

    Time frame: Within 120 hours after administration

  8. Maximum plasma drug concentration (Cmax)

    Cmax is the maximum plasma concentration of TQB3909.

    Time frame: Within 120 hours after administration

  9. Area under the plasma concentration-time curve (AUC0-t)

    To characterize the pharmacokinetics of TQB3909 by assessment of area under the plasma concentration time curve.

    Time frame: Within 120 hours after administration

  10. Plasma elimination half-life (t1/2)

    t1/2 is time it takes for the blood concentration of TQB3909 to drop by half.

    Time frame: Within 120 hours after administration

  11. Undetectable measurable residual disease (U-MRD) ratio of peripheral blood and/or bone marrow.

    Refers to the undetected residual lesions. Peripheral blood and/or bone marrow are used to detect less than 1 CLL cell (less than 10-4) in 10000 white blood cells by flow cytometry.

    Time frame: Up to 34 months

  12. Correlation between potential biomarkers and TQB3909 tablets.

    Correlation of potential biomarkers with TQB3909 tablets: such as BTK and PLCG2 mutation status and allele frequency.

    Time frame: Up to 34 months

07

Study locations

25 of 25 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.

Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's planned 26 months is below that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Jul 25, 2023
StartActual
Oct 11, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05959694
Responsible party
Sponsor
First posted
Jul 25, 2023
Start date
Oct 11, 2023
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Oct 23, 2023

Study contacts

Jianyong Li, Doctor
Contact
Ljianyonglm@mcdmail.com
+86 13951877733
Keshu Zhou, Doctor
Contact
drzhouks77@163.com
+86 13674902391

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bcl-2 Inhibitor TQB3909

Start the discussion